A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.
- SM Goldinger (Author)
- S Gobbi (Author)
- M Ding (Author)
- AL Frauchiger (Author)
- Fink-Puches, R. (Author)
- CD Klemke (Author)
- B Dreno (Author)
- M Bagot (Author)
- C Assaf (Author)
- R Dummer (Author)
Activity: Talk, presentation or poster › Poster